Depression of tumor necrosis factor-α, interleukin-6, and interleukin-10 production: A reaction to the initial systemic hyperactivation in septic shock

Journal of Investigative Surgery

Volumn 10, Issue 6, 1997, Pages 349-355

  Haupt, W ^a   Zirngibl, H ^b   Riese, J ^b   Stehr, A ^b   Linde, H J ^b   Hohenberger, W ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b NONE

Author keywords

Cytokines; Host defense; Immunology; Risk; Septic shock

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOASSAY; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; IMMUNOLOGY; IMMUNOREACTIVITY; INFLAMMATION; INTENSIVE CARE; MORTALITY; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0031399226     PISSN: 08941939     EISSN: None     Source Type: Journal    
DOI: 10.3109/08941939709099598     Document Type: Article

References (31)

1. Darville T, Giroir B, Jacobs R. The systemic inflammatory response syndrome (SIRS): Immunology and potential immunotherapy. Infection. 1993;21:279-290.
2. Goris RJ. Multiple organ failure - whole body inflammation? Schweiz Med Wochenschrift. 1989;119:347.
3. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg. 1992;216:117-134.
4. Baue AE. Multiple, progressive, or sequential systems failure: A syndrome of the 1970's. Arch Surg. 1975;110: 779-789.
5. The APCC/SCCM Consensus Conference Committee, Bone R. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101: 1644-1655.
6. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med. 1993;328: 106-113.
7. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: Pathogenesis. Lancet. 1991; 338:732-736.
8. Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA. 1993;269:1829-1835.
9. Fisher CJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RMH, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334:1697-1702.
10. Fisher CJ, Dhainault JF, Opal SM. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA. 1994; 271:1836-1843.
11. Heath AW. Cytokines and infection. Curr Opin Immunol. 1992;2/3:380-384.
12. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457-469.
13. Billiau A, Vandekerckhove F. Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest. 1991;21: 559-573.
14. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR CDC Surveill Summ. 1990;39: 31-34.
15. Rackow EC, Astiz ME. The pathophysiology and treatment of septic shock. JAMA. 1991;266: 548-554.
16. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JP. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 1991;88:1747-1754.
17. Livingstone DH, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC. Depressed interferon-g production and monocyte HLA-DR expression after severe injury. Arch Surg. 1989;123:1309-1313.
18. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood. 1995; 85:1341-1347.
19. Tracey KJ, Cerami A. Tumor necrosis factor: An updated review of ist biology. Crit Care Med. 1993;21:415-422.
20. De Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE. Interleukin-10. Curr Opin Immunol. 1992;4:314-320.
21. Andus T, Geiger T, Hirano T, Kishimoto T, Heinrich PC. Action of human recombinant interleukin-6, interleukin 1 beta and tumor necrosis factor alpha on the mRNA induction of acute phase proteins. Eur J Immunol. 1988; 18:739-746.
22. Hack CE, De Groot ER, Felt-Bersma RJF. Increased plasma levels of IL-6 in sepsis. Blood. 1989;74:1704-1710.
23. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH. Does endotoxin tolerance prevent the release of inflammatory monokines during sepsis? Arch Surg. 1992;127:191-196.
24. Ziegler-Heitbrock HWL. Molecular mechanism in tolerance to lipopolysaccharide. J Inflammation 1995;45: 13-26.
25. Frankenberger M, Pechumer H, Ziegler-Heitbrock HWI. Interleukin 10 is upregulated in LPS-tolerance. J Inflammation. 1995;45:56-63.
26. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med. 1987;317:659-665.
27. Sweet MJ, Hume DA. Endotoxin signal transduction in macrophages. J Leukocyte Biol. 1996; 60:8-26.
28. Ertel W, Krombach F, Kremer JP, Jarrar D, Thiele V, Eymann J, Muenzing S, Faist E, Messmer K, Schildberg FW. Mechanisms of cytokine cascade activation in patients with sepsis: Normal cytokine transcription despite reduced CD14 receptor expression. Surgery. 1993; 114:243-251.
29. Cannon JG, Tompkins RG, Gelfand JA. Circulating interleukin-1 and tumor necrosis factor in septic shock and endotoxin fever. J Infect Dis. 1990;161:79-84.
30. Calvano Serum, van der Poll T, Coyle SM, Barie BS, Moldawer LL, Lowry SF. Monocyte tumor necrosis factor recetor levels as a predictor of risk in human sepsis. Arch Surg. 1996; 131:434-437.
31. Marchant A, Deviere J, Byl B, de Groote D, Vincent JL, Goldmann M. Interleukin-10 production during septicaemia. Lancet. 1994;343:707-708.